hivandhepatitis.com

Error
  • Article not found
UNAIDS: More than 7 Million Africans on HIV Treatment, Deaths Continue to Fall

UNAIDS: More than 7 Million Africans on HIV Treatment, Deaths Continue to Fall

UNAIDSreports more than 7 million people now on HIV treatment across Africa -- with nearly 1 million added in the last year -- while new HIV infections and deaths from AIDS continue to fall  

READ MORE...

Coverage of the 2013 EASL International Liver Congress

Coverage of the 2013 EASL International Liver Congress

HIVandHepatitis.com coverage of the 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) in Amsterdam, April 24-28, 2013.

Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, and prevention and treatment of hepatocellular carcinoma.

Full listing by topic

EASL 2013 conference section

4/27/13

 

READ MORE...

EASL 2013: Direct-acting Antivirals Boost Response to Pegylated Interferon/Ribavirin

EASL 2013: Direct-acting Antivirals Boost Response to Pegylated Interferon/Ribavirin

For people with chronic hepatitis C who cannot wait for all-oral regimens, interferon-based therapy is still a reality. Researchers at the recent EASL International Liver Congress (EASL 2013) presented promising data showing that several experimental direct-acting antiviral agents (DAAs) can significantly improve response rates without reducing tolerability.

READ MORE...

Coverage of the 2013 Conference on Retroviruses and Opportunistic Infections

Coverage of the 2013 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), March 3-6, 2013, in Atlanta.

Conference highlights include experimental therapies for HIV and hepatitis C, HIV cure research, aging, HIV-related conditions and treatment complications, HIV treatment as prevention and PrEP,  and HIV/HBV and HIV/HCV coinfection.

Full listing by topic  

HIVandHepatitis.com CROI 2013 conference section

READ MORE...

CROI 2013: Functional Cure of HIV-infected Infant after Early ART [VIDEO]

CROI 2013: Functional Cure of HIV-infected Infant after Early ART [VIDEO]

The big news on the opening day of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) was a report about an infant with HIV who started combination antiretroviral treatment very early and now shows no evidence of replication-competent virus. "We equate this to our Berlin Patient," said Deborah Persaud from Johns Hopkins University School of Medicine. "It could get us on the road to a cure for HIV-infected children."

READ MORE...

Coverage of the 2012 AASLD Liver Meeting

Coverage of the 2012 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) in Boston, November 9-13, 2012.

Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.

Full listing by topic

HIVandHepatitis.com AASLD 2012 conference section

READ MORE...

1 of 6 Loading
Some Men Shed HIV in Semen Despite ART, Linked to Herpesvirus Coinfection

Some Men Shed HIV in Semen Despite ART, Linked to Herpesvirus Coinfection

Sangamo Reports Zinc Finger Gene Therapy Leads to Long-term CD4 Cell Gains, Shrinking HIV Reservoirs

Sangamo Reports Zinc Finger Gene Therapy Leads to Long-term CD4 Cell Gains, Shrinking HIV Reservoirs

DDW 2013: Viral Breakthrough May Occur during Interferon/Ribavirin 'Tail' of HCV Triple Therapy

DDW 2013: Viral Breakthrough May Occur during Interferon/Ribavirin 'Tail' of HCV Triple Therapy

DDW 2013: Advanced Fibrosis Does Not Affect Response to Faldaprevir All-oral Regimen

DDW 2013: Advanced Fibrosis Does Not Affect Response to Faldaprevir All-oral Regimen

DDW 2013: Does Treating Herpes Help Suppress Hepatitis C Virus?

DDW 2013: Does Treating Herpes Help Suppress Hepatitis C Virus?

EASL 2013: HIV/HCV Coinfection

EASL 2013: HIV/HCV Coinfection

EASL 2013: Probiotics May Help Manage Hepatic Encephalopathy in Patients with Cirrhosis

EASL 2013: Probiotics May Help Manage Hepatic Encephalopathy in Patients with Cirrhosis

HIV/AIDS

Setting

HIV Treatment

Very Early Antiretroviral Therapy Does Not Prevent Immune Activation

People who started antiretroviral therapy (ART) during acute HIV infection and e...

MORE:

HIV Prevention

Reformulated Tenofovir Gel Found Safe and Acceptable for Anal Sex

 

Men and women found a microbicide gel containing 1% tenofovir -- which has...

MORE:

HIV Testing & Diagnosis

U.S. Preventive Services Task Force Recommends Routine HIV Screening for Adolescents and Adults

On April 30 the U.S. Preventive Services Task Force (USPSTF) issued a "Grad...

MORE:

HIV Disease Progression

Lack of Food Linked to More Hospitalizations among HIV+ People with Unstable Housing

Homeless and marginally housed people with HIV in San Francisco who experienced ...

MORE:

Hepatitis B

Setting

HBV Treatment

EASL 2013: Do Asian Patients Respond Better to Pegylated Interferon for Hepatitis B?

Some Asian people with chronic hepatitis B treated with pegylated interferon may...

MORE:

HBV Prevention

FDA Rejects Heplisav Hepatitis B Vaccine Seeking More Safety Data

The U.S. Food and Drug Administration (FDA) has declined to approve Dynavax...

MORE:

HBV Testing & Diagnosis

National Hepatitis Testing Day: Most Infected Are Unaware, All Boomers Should Get HCV Test

In advance of the National Hepatitis Testing Day on Saturday, May 19, the U.S. C...

MORE:

HBV Disease Progression

Everolimus (Zortress) Approved to Prevent Liver Transplant Rejection

The U.S. Food and Drug Administration (FDA) this month approved the immunos...

MORE:

Hepatitis C

Setting

HCV Treatment

EASL 2013: Anemia Is a Common Side Effect of First-generation HCV Protease Inhibitors

About half of patients taking boceprevir (Victrelis) or telaprevir (Incivek or I...

MORE:

HCV Prevention

Tattoos Are Associated with Hepatitis C Virus Infection in the Absence of Other Risk Factors

Individuals with chronic hepatitis C virus (HCV) infection in New York City were...

MORE:

HCV Testing & Diagnosis

Sunday is Hepatitis Testing Day -- All Baby Boomers Should Get Hep C Test

May 19 is the second annual Viral Hepatitis Testing Day, an opportunity to raise...

MORE:

HCV Disease Progression

Liver Cancer Increasing among People with HIV/HCV Coinfection

Hepatocellular carcinoma (HCC) is a growing problem among HIV positive people co...

MORE:

HIV/Hepatitis Coinfection

Setting

HIV/HBV Coinfection

Tenofovir plus Emtricitabine or Lamivudine Does Not Always Suppress Hepatitis B in HIV/HBV Coinfected

HIV/HBV coinfected people with high hepatitis B virus (HBV) levels and those who...

MORE:

HIV/HCV Coinfection

AASLD 2012: Final Study Results Show Telaprevir Is Safe and Effective for HIV/HCV Coinfected Patients

HIV/HCV coinfected people treated with telaprevir (Incivek) triple therapy are s...

MORE:

HBV/HCV Coinfection

Adefovir plus Hepatitis C Therapy May Prevent HBV Reactivation in HBV-HCV Coinfected Patients

Due to the similar transmission routes, many people are dually infected with bot...

Other Health News

Setting

Tuberculosis (TB)

World TB Day: U.S. Cases Hit New Low, Integration with HIV Care Needed Worldwide

The number of new tuberculosis (TB) cases in the U.S. fell below 10,000 in 2012 ...

MORE:

Human Papillomavirus (HPV)

Does Human Papillomavirus Contribute to Lung Cancer?

A small proportion of lung cancers may be caused by the same high-risk strains o...

MORE:

Other STDs

Drug-resistant Gonorrhea Makes its Way into North America

The first documented failure of oral treatment for gonorrhea in North America ha...

MORE:

Influenza

2012-2013 Could Be Bad Flu Season, Not Too Late to Get Vaccine, CDC Advises

Significant increases in influenza activity in the U.S. during the past 2 weeks ...

MORE:
Copyright © 2013 hivandhepatitis.com. All Rights Reserved. Designed by JoomlArt.com. Joomla! is Free Software released under the GNU General Public License.

Bread and Roses Web DesignWeb Design and Development by Bread and Roses Web Design